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Tobacco use is considered the single most important man-made cause of cancer 
that can be avoided. The evidence that nicotine is involved in cancer development is 
reviewed and discussed in this paper. Both tobacco smoke and tobacco products for 
oral use contain a number of carcinogenic substances, such as polycyclic hydrocarbons 
and tobacco-specific N-nitrosamines (TSNA), which undoubtedly contribute to tobacco 
related cancer. Recent studies have shown that nicotine can affect several important 
steps in the development of cancer, and suggest that it may cause aggravation and 
recurrence of the disease. TSNA may be formed from nicotine in the body. The role of 
nicotine as the major addictive component of tobacco products may have distracted our 
attention from toxicological effects on cell growth, angiogenesis, and tumor malignancy. 
Effects on cancer disease are important aspects in the evaluation of possible long-term 
effects from sources of nicotine, such as e-cigarettes and products for nicotine replace-
ment therapy, which both have a potential for life-long use.
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introduction
Nicotine is the major chemical component responsible for addiction in tobacco products. At a high 
pH (alkaline), nicotine is in the non-ionized state and can be readily absorbed across the epithelium 
of the lung, the oral mucosa, the nose, and through the skin. A person smoking 25 cigarettes/day 
will absorb about 0.43 mg nicotine/kg bodyweight (1) and obtain a nicotine blood concentration 
in the range 4–72 ng/ml (0.025–0.444 μM) (2). The halftime of nicotine in plasma is about 2 h (3).
More than 80% of the nicotine absorbed undergoes metabolism in the liver, primarily by CYP2A6, 
UDP-glucuronosyltransferase, and a flavin-containing monooxygenase. Cotinine is the major metab-
olite. Nornicotine, formed by demethylation of nicotine is both a metabolite of nicotine and a minor 
Abbreviations: α-BTX, α-bungarotoxin; β-AR, β-adrenergic receptor; Ach, acetylcholine; CA, chromosomal aberration; 
CI, confidence interval; CPA, cyclophosphamide; CRT, chemoradiotherapy; DMBA, 7,12-dimethylbenz[a]anthracene; DSB, 
double-strand breaks; EBRT, external beam radiotherapy; EGF, epidermal growth factor; EGFR, epidermal growth factor recep-
tor; EMT, epithelial–mesenchymal transition; FANFT, N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide; HR, hazard ratio; IARC, 
International Agency for Cancer Research; MAP, mitogen-activated protein; MNNG, N-methyl-N′-nitro-N-nitrosoguanidine; 
nAChRs, nicotinic acetylcholine receptors; MN, micronuclei; NMU, N-nitrosomethylurea; NNAL, 4-(methylnitrosamino)-
1-(3-pyridyl)-1-butanol; NNK, 4-(metylnitrosamino)-1-(3-pyridyl)-1-butanon); NNN, N′-nitrosonornicotine; NRT, nicotine 
replacement therapy; PAH, polycyclic hydrocarbons; RT, radiotherapy; SCE, sister chromatide exchange; SSB, single-strand 
breaks; TSNA, tobacco-specific N-nitrosamines.
TABLe 1 | Level of NNAL in urine from smokers, users of ‘‘old” snuff in 
USA (smokeless tobacco), users of ‘‘modern” Swedish snus and of NRT 
compared to people exposed to eTS (17, 18, 21).
Group Total NNAL (pmol/mg creatinine)
Smokers 2.6 (0.3–3.9)a
Snuff (old type) 3.3 (1.5–5.1)
Swedish snus 1.4 (0.9–2.0)
NRT 0.3 (0.1–0.4)
Non-smokers exposed to ETS 0.042 ± 0.020b
a95% Confidence interval.
b±SD.
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tobacco alkaloid. As much as 85–90% of nicotine is metabolized 
before elimination via renal excretion (1). Cotinine blood concen-
tration in smokers is 200–400 ng/ml (1.1–2.2 μM) (3).
Nicotine exerts its effects via stimulation of the nicotinic ace-
tylcholine receptors (nAChRs), which are located in the CNS, at 
interganglionic junctions of the autonomic nervous system, and 
on target organs throughout the body as part of the parasympa-
thetic autonomic nervous system. nAChRs are ligand-gated ion 
channels composed of five membrane-spanning subunits that 
combine to form a functional receptor (4). The homomeric α7-
nAChR has been implicated as the primary receptor facilitating 
nicotine-mediated cell proliferation, but other receptor subunits 
may also be involved (5). Nicotine binds to nAChRs with a higher 
affinity than acetylcholine (Ach). It should be noted that tobacco-
specific N-nitrosamines (TSNA) and cotinine may also bind to 
nAChRs (5–7).
The binding of nicotine to nAChR in the brain is involved in 
the rewarding effects of nicotine and in the adaptations that occur 
in response to chronic exposure, which give rise to dependence 
and to withdrawal responses. The positive reinforcing aspects of 
nicotine addiction primarily results from the release of dopa-
mine (1).
Several lines of evidence indicate that nicotine may contribute 
to the development of cancer. Evidence from experimental in vitro 
studies on cell cultures, in vivo studies on rodents as well as stud-
ies on humans inclusive of epidemiological studies indicate that 
nicotine itself, independent of other tobacco constituents, may 
stimulate a number of effects of importance in cancer develop-
ment (5, 6).
endogenous Formation of TSNA
Tobacco-specific N-nitrosamines is formed by N-nitrosation of 
alkaloids in tobacco (Figure  1). NNN (N′-nitrosonornicotine) 
and NNK (4-(metylnitrosamino)-1-(3-pyridyl)-1-butanon) 
are among the most important and most potent carcinogens in 
tobacco and tobacco smoke. NNAL (4-(methylnitrosamino)-1-
(3-pyridyl)-1-butanol) is a metabolite of NNK and determination 
of total NNAL (NNAL and its glucuronides) in urine is often 
used to assess the possible role of TSNA in tumor development. 
A significant relationship between total NNAL has been found in 
serum samples from smokers and lung cancer risk (8). NNN and 
NNK are classified by International Agency for Cancer Research 
(IARC) as human carcinogens (9, 10).
It is well known that NNN and NNK are present both in main-
stream and sidestream cigarette smoke and in moist snuff (11). 
In the 1996 review, Bartsch and Spiegelhalder (12) pointed out 
that N-nitrosamines may be formed endogenously in humans. 
Endogenous formation of TSNA has been demonstrated in rats 
treated with tobacco alkaloids and NaNO2 (13, 14).
It was claimed in some early studies that NNK is not formed 
in vivo (13, 15), but more recent data do not support this view. 
Thus, although the level of NNK in the Swedish snus is much 
lower than in the old type of snuff and in cigarette smoke (16), 
the level of total NNAL (a NNK metabolite) in urine from users of 
Swedish snus is still considerable, and only reduced to about half 
of that found in smokers and in users of old type snuff (Table 1). 
The level of total NNAL is also increased among users of nicotine 
replacement therapy (NRT) (17) compared with non-smokers 
exposed to ETS (18). It is of interest that the risk of cancer of the 
pancreas appears not to diverge materially between the different 
tobacco products (9). It has also been reported that NNN can be 
formed from nornicotine in human saliva (in vitro) (19). Recently, 
Hecht et al. (20) reported that the urine from users of e-cigarettes 
had very low levels of NNAL, which may suggest that endogenous 
formation of TSNA after nicotine inhalation is negligible. The 
above results indicate that TSNA may be formed endogenous 
after absorption of nicotine through the mucous membranes in 
the oral cavity and through the skin, while formation after lung 
absorption may be negligible. Thus, the toxicokinetics of nicotine 
may depend on the route of administration.
Genotoxicity of Nicotine
Most studies with the Salmonella assay (including urine of rats 
exposed to nicotine) were negative. However, nicotine has been 
FiGURe 1 | Formation of NNK, NNN, and NNAL.
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shown to induce DNA damage in the Escherichia coli pol A+/
pol− test (22).
Two studies were positive for chromosomal aberration (CA) 
and sister chromatid exchange (SCE) in experiments with the 
CHO cell line (23, 24). These results have later been confirmed 
by Ginzkey et al. (25) in experiments with human lymphocytes. 
They found a significant increase in CA and SCE at a concen-
tration of 1 μM nicotine (lowest concentration tested), which 
is only a factor of 2–3 higher than that found in the blood of 
smokers (2). DNA double-strand breaks (DSB) with missing 
repair are considered to be the most important lesion leading 
to observed CA.
In studies with the ‘‘Comet” assay, effects of nicotine has 
been reported in human nasal mucosa (26, 27), tonsillar tissue 
(28), cells of the parotid gland (29), and spermatozoa (30). On 
the other hand, Ginzkey et al. (25) did not observe any effect of 
nicotine in human lymphocytes after 24 h incubation. Since the 
Comet assay is known to detect DNA single-strand breaks (SSB), 
alkali-labile sites, and incomplete excision-repair sites in prolifer-
ating and non-proliferating cells, the authors argued that the lack 
of effects could be due to possible repair of DNA single-strand 
breaks during the 24 h incubation.
Argentin and Cicchett (31) studied formation of micronuclei 
(MN) by nicotine with human gingival fibroblasts and found 
that treatment with 1  μM nicotine significantly enhanced the 
frequency of MNs. Additions of antioxidants minimized the 
effect of nicotine by decreasing significantly the MN formation. 
Induction of MN was likewise found in a study with human 
lymphocytes (25), although a higher nicotine concentration 
was needed (100 μM). The mechanisms leading to the forma-
tion of MN are chromosome breakage and disturbance of the 
chromosome-segregation system, thus MN formation represents 
an irreversible DNA damage.
Adduct formation between nicotine and DNA has been 
reported by Cheng et al. (32). However, this has not been verified 
in a newer study by Hecht (33).
The mechanisms responsible for the genotoxic effects caused 
by nicotine have not been established. It is, however, of impor-
tance that effects are observed at concentrations of nicotine not 
much higher than those found in blood of smokers. The findings 
that the effects of nicotine are reduced in the presence of anti-
oxidants suggest that oxidative radicals are involved. Moreover, 
the decrease in DNA damage reported after co-incubation with 
a nAChR antagonist indicates a receptor-dependent pathway for 
induction of oxidative stress (27).
In Vitro Studies on Cell Cultures
Signaling Pathways
Low concentrations of nicotine stimulate cell proliferation, 
while high concentrations are cytotoxic (34). The concentra-
tions of nicotine that stimulate cell proliferation correspond to 
the concentrations found in the bloodstreams of smokers and 
of users of oral tobacco. In this connection, it is of importance 
that nAChRs are also expressed on non-neuronal epithelial 
and endothelial cells and the nicotine stimulation of cell pro-
liferation is inhibited by nAChR antagonists (35). It has been 
proposed that nicotine promotes cell division by upregulating 
of cyclin D1 (36).
The binding of nicotine and other nicotine metabolites to the 
nAChRs, stimulate signaling pathways and reactions that increase 
cell proliferation and cell survival. The nicotine-mediated secre-
tion of epidermal growth factor (EGF) via nAChRs results in 
transactivation of epidermal growth factor receptor (EGFR) and 
activation of mitogenic and antiapoptotic pathways (37, 38). 
The nicotine-mediated release of adrenaline and noradrenaline, 
which are the physiologic ligands for β-adrenergic receptors (β-
ARs), leads to the binding to and activation of β-AR. This results 
in stimulation of multiple oncogenic and mitogenic signaling 
cascades, which activates proliferative pathways and the release 
of EGF, vascular endothelial growth factor (VEGF), and arachi-
donic acid (39–41). In addition, it has been found that nicotine 
itself binds to β-ARs (39).
Nicotine induces epithelial–mesenchymal transition (EMT), 
which is one of the vital steps for the acquisition of malignant 
phenotype. This transition allows the cell to acquire migratory 
properties, which may facilitate cancer metastases (42).
Nicotine decreases the tumor suppressor Chk2, which is acti-
vated by DNA damage. The decrease in Chk2 in cells exposed to 
nicotine suggests that nicotine may be capable of overriding DNA 
damage checkpoint activation, disrupting genetic surveillance, 
and increasing the risk of oncogenesis (43).
Angiogenic Growth
Nicotine promotes endothelial cell migration, proliferation, sur-
vival, tube formation, and nitric oxide (NO) production in vitro, 
mimicking the effect of other angiogenic growth factors (44, 45). 
In 2001, it was found that nicotine was a potent angiogenic agent 
at tissue and plasma concentrations similar to those induced by 
light to moderate smoking (46). Effects of nicotine on angiogen-
esis have been demonstrated for a number of tumor cells, such 
as breast, colon, and lung (47, 48). Similar results have also been 
demonstrated in in  vivo mouse models of lung cancer, where 
nicotine significantly increased the size and number of tumors in 
the lung, and enhanced metastasis (49).
interference with Cancer Therapy
In several in vitro experiments, it has been found that nicotine in 
concentrations as low as 1 μM decreased the anti-proliferative and 
pro-apoptotic effects exerted by chemotherapeutics on several 
different malignant cell lines (50–52). These effects were partially 
reverted by exposure to α-bungarotoxin (α-BTX), an inhibitor 
of α7-nAChR (51). In the case of radiotherapy (RT), nicotine 
administration increased survival of H460 and A549 lung cancer 
cells. This effect was likewise reduced by addition of α-BTX 
prior to nicotine addition and radiation (53). On this basis, it is 
expected that use of nicotine products during cancer treatment 
may reduce the effects due to reactions following interaction of 
nicotine with α7-nAChR.
It was found in 1998 (54) that nicotine activates the mitogen-
activated protein (MAP) kinase signaling pathway in lung cancer 
cells. This results in increased expression of the bcl-2 protein 
and inhibition of apoptosis. These effects may also contribute to 
reduction of the effect of chemotherapy in smokers (44).
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Cotinine
Cotinine was found to increase significantly proliferation of the 
human lung adenocarcinoma A549 cells at a concentration of 
0.1 μM. The effect was abolished by the phosphoinositide 3-kinase 
inhibitor LY294002 (55). Moreover, it was found that cotinine 
in a concentration of 0.01  μM inhibited doxorubicin-induced 
apoptosis by suppressing caspase-mediated apoptosis. Caspases 
or cysteine-aspartic proteases are essential for programed cell 
death. The results suggested that cotinine suppressed apoptosis 
through the PI3K/Akt pathway just as nicotine does.
In Vivo Studies on Rodents
Carcinogenicity Studies with Nicotine
A group of 68 female Sprague-Dawley rats was exposed 20  h 
5 days/week to nicotine by inhalation (56). The control group 
consisted of 34 animals. The nicotine concentration in air was 
500  μg/m3 (nicotine concentration in plasma slightly above 
100 ng/ml in exposed rats). Forty-four (65%) exposed rats and 
17 (50%) controls were alive after 1 year and 30 (44%) exposed 
and 9 (26%) controls after 1.5  years. At the end of the study 
(after 24 months) the remaining rats, 22 (32%) nicotine exposed 
animals and 7 (21%) controls – were sacrificed and examined 
for tumors. The fraction of tumors in the pituitary gland was 
higher in the exposed group (5/59 versus 0/25). However, it is 
difficult to evaluate the results as the time of tumor identifica-
tion is not given. Moreover, due to the low sensitivity of animal 
experiments, the doses used in animal experiments to evaluate 
potential carcinogenic effects are usually several times higher 
than those that human may be exposed to. Normally the highest 
dose used in an animal experiment should result in a toxicity 
giving about 10% decreased weight. In the present experiment, 
the plasma nicotine level was only slightly higher than that of 
smokers, and the decrease in weight at 24 months was only 3% 
in the exposed animals compared to the controls. Thus, the 
exposure doses used and the missing of important information 
in the paper prevent the drawing of firm conclusions from the 
experiment.
Female A/J mice received subcutaneous (s.c.) injections of 
nicotine hydrogen tartrate (3  mg/kg  bw/day, 5  days/week for 
24 months), while a control group received saline injections (57). 
The study showed that 73% of the nicotine-treated mice but none 
of the control mice developed neoplasms originating from the 
uterus or skeletal muscle. The uterine tumors were diagnosed as 
leiomyosarcoma, and those in quadriceps as rhabdomyosarcoma. 
No metastases were observed. Rhabdomyosarcoma can develop 
spontaneously in A/J mice, but leiomyosarcoma does not (58), 
which indicates that the leiomyosarcoma development was 
specific to the experimental nicotine treatment. Thus, the experi-
ment may suggest that nicotine is a complete carcinogen.
Male Syrian golden hamsters maintained in 60% hyperoxia 
and receiving s.c. injections of nicotine for the duration of their 
life (up to 64 weeks) developed a low but significant number of 
tumors (2/16 adenocarcinoma of the nasal cavity, one of these 
hamsters had also an adenocarcinoma of the adrenal gland, and 
2/16 carcinomas and 2/16 adenomas of the lung) (59). No metas-
tases were observed. Hamsters receiving nicotine and maintained 
in ambient air or given saline injections and maintained in 60% 
hyperoxia did not develop tumors in any organs.
Addition of nicotine hydrogen tartrate in the drinking water 
of female Wistar Han rats and female C57Bl/6 mice for 4 weeks 
induced hyperplasia of the urinary bladder epithelium (60). 
These results may be consistent with induction of an early-stage 
carcinogenicity; however, no conclusion can be drawn from this 
4-week study.
Except for the inhalation experiment by Waldum et al. (56), 
no long-term animal experiments of the type normally used to 
evaluate carcinogenicity are available for nicotine. Due to several 
shortcomings, no conclusion can be drawn from this study. Results 
from experiments with injections are generally considered to be 
of less importance in evaluation of carcinogenicity unless the 
tumors induce metastases. Thus, at present it is not possible to 
draw any conclusion with regard to the potential carcinogenic 
effect of long-term treatment with nicotine.
Cocarcinogenicity and Promoter Activity
Nicotine showed cocarcinogenic effect with DMBA 
(7,12-dimethylbenz[a]anthracene) in the hamster cheek pouches 
model (61) and promoter activity with MNNG (N-methyl-N′-
nitro-N-nitrosoguanidine) as initiator in a rat stomach model 
(62). In the above experiments, no effect was found when treated 
with nicotine alone.
No effects of nicotine were found with NMU 
(N-nitrosomethylurea) as an initiator in a rat mammary tumor 
model. However, 100% of the animals treated with NMU alone 
developed tumors (63). It was reported in a rat experiment (64) 
with hormone-dependent autochthonous mammary carcinomas 
induced by HECNU, a water-soluble nitrosourea, that nicotine 
had an antitumor effect. Both trans-nicotine-N′-oxide and a mix-
ture of cis- and trans-nicotine-N′-oxides promoted induction of 
forestomach tumors in the rat, but not urinary bladder tumors 
after initiation with FANFT (N-[4-(5-nitro-2-furyl)-2-thiazolyl]
formamide). Cotinine was also tested as promoter, but had no 
effect (65).
initiation by NNK
Five experiments have been identified in mice with NNK (100 mg/
kg bw, weekly in 1–5 weeks) as an initiator and nicotine as a pro-
moter. Nicotine was administered by i.p. injections (1 mg/kg bw, 
three times a week for 10–28 weeks) in two experiments (49, 66) 
and in the drinking water (0.07–0.1 mg/ml) for 12–44 weeks in 
three experiments (55, 67, 68). Nicotine showed promoter activ-
ity in the two experiments after i.p. injection, while only a small 
non-significant or no promoter activity was found after nicotine 
in the drinking water. It is unlikely that the difference in the effect 
of nicotine is due to the administration of the initiator NNK, as 
the dose per injection was the same in all experiments. Moreover 
in the experiments with i.p. injection of nicotine, the number of 
NNK injections was only one in the experiment of Iskandar et al. 
(66). In the drinking water experiments, the mice received 1–3 
NNK injections. Moreover, it is unlikely that the difference can 
be accounted for by the time span of the promotion period, which 
ranged from 10 to 28 weeks for the i.p. injection experiments and 
from 12 to 44 weeks in the drinking water experiments. Thus, the 
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different results are most likely due to the route of administration 
of nicotine, as the parietal part of the peritoneum drains directly 
to the systemic circulation.
The levels of nicotine and cotinine in blood and urine have 
only been measured in a few studies. The most interesting 
observation is the low level of nicotine and cotinine in serum 
observed by Murphy et al. (68) after addition of nicotine to the 
drinking water. They found 0.26  ng/ml of nicotine and 29  ng/
ml of cotinine. The ratio of cotinine/nicotine is thus about 100. 
No serum values are available from the other studies. However, 
Zhou et al. (69) measured nicotine and cotinine in serum after 
i.p. injection of 1 mg/kg bw in CYP2A5 WT mice. They found a 
nicotine level of 45 ng/ml, which decreased to 0 after 60 min and a 
cotinine level 300 ng/ml, which decreased to 0 after 240 min. The 
ratio of cotinine/nicotine is thus about 5 and the level of nicotine 
was more than 100 times higher than that observed by Murphy 
and coworkers (68). The cotinine concentration after human use 
of tobacco products are in general 10 times or less higher than the 
nicotine concentration when measured simultaneously in serum 
or other tissues (1, 70). The reason for the large difference may 
be that the drinking water experiments have a considerable first-
pass metabolism of nicotine in liver before it enters the systemic 
circulation and less control of how much the mice were drinking 
and thus their total nicotine intake. Matta and coworkers (71) 
point out that only about 30% of orally administered nicotine 
can be expected to reach the circulation, while the other 70% 
are metabolized primarily to cotinine before reaching the blood 
stream. The results of the measurements immediately after i.p. 
injections of nicotine were similar to that found among smokers 
of about 25 cigarettes/day. The lacking effects of nicotine in the 
drinking water experiments may thus be related to low serum 
nicotine levels.
Most of the experiments involving promotion after initiation 
with NNK have been carried out with A/J mice as this strain is 
highly susceptible to lung carcinogens, while C3H and C57BL/6 
mice are relatively resistant. The mechanism(s) of different 
susceptibility are not known and may be multifactorial. It has 
been reported that NNK causes a significant increase in the 
expression of α7-nAChRs and COX-2 in the A/J lung, which 
might contribute to its higher susceptibility to NNK-induced 
lung tumorigenesis (72).
effects on Tumor Progression
Six experiments related to the effect of nicotine on tumor progres-
sion have been identified. In these experiments, malignant cells 
were injected in mice and the mice were subsequently treated 
with nicotine. In two experiments where nicotine was admin-
istered in drinking water, no effect of nicotine was observed. In 
the first study by Jarzynka et al. (73), ovariectomized nude mice 
received nicotine (0.2 mg/ml drinking water) for 5 weeks after 
implantation of human A549 bronchioloalveolar carcinoma cells. 
If the mice also received estradiol, the tumor sizes increased 
significantly. In the other experiment by Maier et al. (67), AB6F1 
mice received nicotine 0.1 mg/ml in drinking water or i.p. injec-
tion with nicotine 0.8 mg/kg bw three times a week for 2–5 weeks 
after injection of CL13, IO33, or CL25 cells (all cell lines were 
derived from a lung adenocarcinoma). Neither i.p. injection of 
nicotine nor nicotine drinking water did enhance tumor growth 
or formation of metastases. The authors suggested that nicotine 
has a dose threshold, below which it has no appreciable effect.
On the other hand, Davis et al. (49) implanted subcutaneously 
Line1 mouse adenocarcinoma cells into syngenic BALB/c mice 
and observed that subsequent administration of nicotine by 
i.p. injections or transdermal patches enhanced tumor growth, 
metastases formation and tumor recurrence. The authors pointed 
out that mice receiving nicotine by i.p. injections had an average 
cotinine concentration of 3 μg/ml in urine and those that received 
nicotine by transdermal patch had an average cotinine concentra-
tion of 5 μg/ml. In human smokers, cotinine concentrations in 
urine have been reported in values ranging from 1.5 to 8.0 μg/
ml. Al-Wadei et al. (74) inoculated male athymic nude mice by 
s.c. injection with Panc-1 cells (cell line isolated from a human 
pancreas cancer) and found that 0.2 mg/ml nicotine in drinking 
water increased the xenograft volumes significantly. In a study with 
Lewis in vivo lung cancer model, Nakada et al. (55) reported that 
both nicotine (0.1 mg/ml) and cotinine (0.1 mg/ml) in drinking 
water significantly increased tumor growth after implementation 
of Lewis lung carcinoma cells in mice. Moreover, both nicotine 
and cotinine accelerated capillary formation of vascular endothe-
lial cells. Heeschen et al. (46) studied if nicotine could enhance 
tumor angiogenesis in the Lewis lung cancer model. Sixteen days 
after implantation of the cancer cells and treatment with nicotine 
(0.1  mg/ml), tumor growth in the nicotine group markedly 
exceeded that in the vehicle-treated group and required killing of 
the mice. This acceleration of tumor growth in the nicotine group 
corresponded with increased vascularization of the tumor tissue. 
In a subsequent experiment, it was found that antagonists of the 
nAChR abolished the proangiogenic effect of nicotine. Nicotine 
enhanced tumor progression in four of the six experiments. 
Enhancements were found both after exposure of nicotine by i.p. 
injection, oral, and skin administrations. Moreover, cotinine did 
also enhance tumor growth.
Reduced Protection from Cancer 
immunosurveillance
Smokers are less responsive to vaccines (75, 76). However, the 
mechanism for this effect on host immunity is not known. A 
general immunosuppressive effect of nicotine was shown by 
decreased interleukin-2 (IL-2) production in mitogen-stimulated 
human peripheral blood mono-nuclear cells (77). Nouri-Shirazi 
and Guinet (78) demonstrated that animals exposed to nicotine 
produced an inadequate effector/memory T cell population 
in response to protein-based vaccine formulated with Th1 
adjuvants. In addition, the prime-boost vaccination recalled 
insufficient memory response and failed to protect the animals 
from an otherwise prophylactic and therapeutic vaccine. It has 
also been reported that exposure to nicotine adversely affects 
dendritic cells, a cell type that has an important role in anticancer 
immunosurveillance (79).
Chemotherapy and Radiotherapy
As early as 1988, Berger and Zeller (80) reported that the 
antitumor effect of cyclophosphamide (CPA) on transplanted 
rat L5222-leukemia was reduced by administration of nicotine. 
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However, using a mammary carcinoma model, it was found that 
administration of nicotine resulted in greater tumor inhibition 
than the antitumor drug HECNU alone. The authors pointed out 
that further combination studies with other classes of cytotoxic 
drugs are warranted.
Warren et al. (53) studied the role of nicotine on response to 
RT and chemoradiotherapy (CRT) in vivo. Male athymic nude 
Foxn1nu mice were inoculated with H460 human lung cancer 
cells to form single xenografts in the right rear flank. Nicotine 
administration during fractionated RT or CRT (5-day treatment) 
increased xenograft regrowth as compared to RT or CRT alone. 
The observation that short-term nicotine (every other day for 
6 days) produced similar tumor regrowth curves as long-term 
nicotine (every other day during treatment, maximum 28 days) 
further suggests that nicotine exposure specifically during treat-
ment is the critical determinant of therapeutic outcome. Further 
analysis demonstrates that nicotine appears to increase HIF-1α 
(hypoxia-inducible factor 1, alpha subunit) expression in  vivo 
with no change in a clinical marker of tumor hypoxia (immuno-
histochemical CAIX expression). The authors emphasized that 
the in vivo effects of nicotine on therapeutic response support 
nicotine as an important systemically available component of 
tobacco for decreasing the efficacy of cancer treatments.
Banerjee et al. (52) inoculated subcutaneously male athymic 
nude mice in the flank region with pancreatic ductal adenocar-
cinoma BXPC-3 cells. The mice were treated either with 50 mg/
kg bw gemcitabine twice a week by i.p injections, 1 μM nicotine 
in the drinking water or with both nicotine in the drinking water 
and gemcitabine i.p. injections. All treatments started 1 day after 
s.c. inoculation of the tumor cells and the animals were observed 
for 30 days. Treatment of mice with gemcitabine alone reduced 
xenograft volumes in weeks 2–4 with 20%. Nicotine treatment 
significantly (p < 0.001) reduced this therapeutic effect of gem-
citabine in weeks 2–4). In accord with the documented ability 
of gemcitabine to induce apoptosis, BXPC-3 xenografts of the 
animals treated with gemcitabine alone showed induced protein 
levels of cleaved caspase-3. By contrast, the induction of cleaved 
caspase in response to gemcitabine was completely abolished by 
nicotine (p < 0.001).
Due to the effects of nicotine during in vivo chemotherapy and 
RT, concern of the use of NRT in relation to cancer treatment has 
been expressed (52, 53). The advantage of NRT is that it does not 
contribute the large number of carcinogens present in tobacco 
smoke (53).
effects on Humans
To our knowledge, there are no relevant study in humans on 
carcinogenic effects from pure nicotine including products, such 
as NRT and e-cigarettes. Observational studies on smokers and 
users of oral tobacco may still provide important suggestions on 
potential effects – as exposures to some of the tobacco-specific 
constituents may be similar. Nicotine is a tobacco component 
where blood concentrations are similar during smoking and use 
of oral tobacco (81). Therefore, relevant effects from tobacco use 
in humans will be briefly reviewed.
Use of Tobacco Prior to Cancer Diagnoses
A higher risk of death from cancer among current users of tobacco 
than among never users, which include both smoking and oral 
smokeless tobacco, has been demonstrated for a number of differ-
ent types of cancer in the literature [see, e.g., Ref. (82–93)]. Only 
a few studies will be discussed in the present section.
Nordenvall et  al. (90) studied the use of tobacco and risk 
of death in cancer patients among 336,381 Swedish construc-
tion workers. A total of 40,230 cases of cancer were identified. 
Hazard ratios and 95% confidence intervals (CIs) for death from 
any cause, cancer-specific death and death from other causes 
were analyzed. Never users of any tobacco served as reference. 
Increased risks of cancer-specific death were observed both 
among exclusive smokers (HR = 1.15, 95% CI: 1.10–1.21) and 
never-smoking snus users (HR =  1.15, 95% CI: 1.05–1.26). It 
should be noted that in the case of snus users, the major part 
of nicotine is absorbed through the oral mucosa. The authors 
pointed out that nicotine may be the common cause to explain 
these findings.
It is of interest that the effects are not limited to patients suffer-
ing from tobacco-related cancers. Although smoking is not likely 
to be a risk factor for initiating prostate cancer, men who are smok-
ing cigarettes before diagnosis appear to have a worse prognosis 
(87, 89, 93, 94). Wilson et al. (93) recently reported in an abstract 
a study on 9582 men with prostate cancer among Swedish con-
struction workers. Compared to never users of tobacco, exclusive 
smokers were at increased risk of both prostate cancer mortality 
(HR = 1.15, 95% CI: 1.05–1.27) and total mortality (HR = 1.17, 
95% CI: 1.09–1.26). Exclusive snus users also had increased risks 
for both prostate cancer mortality (HR = 1.24, 95% CI: 1.03–1.49) 
and total mortality (HR = 1.19, 95% CI: 1.04–1.37). The authors 
concluded that the results suggest that nicotine may promote 
cancer progression independent of the combustion products of 
tobacco smoke.
Use of Tobacco After Diagnosis and During 
Cancer Treatment
People who have used tobacco after a cancer diagnosis and during 
cancer treatment have also used tobacco prior to their diagnoses. 
In studies where survival or recurrence have been assessed, it is 
difficult to differentiate between the contribution of tobacco use 
prior to diagnoses and during cancer treatment. Moreover, the 
studies are primarily on people smoking and only to a limited 
extent on other types of nicotine-containing substances, such as 
oral tobacco. Some studies where it is specifically stated that the 
patients smoked during treatment are discussed below.
It is well known that smoking has an adverse effect in relation 
to surgery. This has also been demonstrated for cancer surgery. 
An example is the study of Sørensen et al. (95) on 425 patients 
that underwent different forms of breast cancer surgery as simple 
mastectomy, modified radical mastectomy, or breast conserving 
surgery in a hospital in Denmark. The authors concluded that 
independent of other risk factors, smoking is predictive for 
post-mastectomy wound infection, skin flap necrosis, and epi-
dermolysis. The effects were in all cases larger for heavy smoking 
than for light smoking.
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In a study of prostate cancer, patients who continued to 
smoke after radical prostatectomy had a higher recurrence than 
former smokers (34.3 versus 14.8%) (96). Steinberger et al. (97) 
followed 2358 patients receiving external beam radiotherapy 
(EBRT) between 1988 and 2005 for clinically localized prostate 
cancer. Current smoking significantly increased the risks of 
both prostate-specific antigen relapse [HR = 1.37 (1.04–1.84)], 
distant metastases [HR 2.30 (1.57–3.36)], as well as prostate 
cancer-specific death [HR = 2.25 (1.30–3.88)]. Moreover, cur-
rent and former smokers, regardless of duration and quantity 
of exposure, had an increased risk of long-term genitourinary 
toxicity after EBRT.
It is agreed that smoking cessation during treatment for 
cancer does in general result in better response and increased 
survival (98). This conclusion is based both on in vitro and in vivo 
experiments as well as epidemiological studies. Nicotine may be 
involved in these effects.
Conclusion
All tobacco products contain various amounts of carcinogenic 
substances, such as polycyclic hydrocarbons (PAH) and TSNA, 
which undoubtedly play an important role in development 
of cancer. Evidence from experimental in  vitro studies on cell 
cultures, in vivo studies on rodents as well as studies on humans 
inclusive of epidemiological studies indicate that nicotine may 
contribute in cancer development by stimulating a number of 
important processes. Nicotine acts primarily by activation of 
nicotine acetylcholine receptors (nAChRs) and nicotine binds 
to these receptors with a higher affinity than acetylcholine. 
Furthermore, the TSNA substances NNN (N′-nitrosonornicotine) 
and NNK (4-(metylnitrosamino)-1-(3-pyridyl)-1-butanon) may 
be formed from nicotine after oral administration. The role of 
nicotine in carcinogenesis is of great importance in the evaluation 
of potentially harmful effects from non-tobacco related sources of 
nicotine, such as e-cigarettes and NRT.
Nicotine has been shown to induce CA, SCE, single-strand 
DNA strand breaks, and MN in vitro. Oxidative stress is probably 
involved since the effects are reduced in the presence of anti-
oxidants. The finding that the effects decrease after co-incubation 
with a nAChR antagonist indicates a receptor-dependent pathway 
for induction of oxidative stress.
The interaction of nicotine with nAChRs activates signaling 
pathways that result in a number of reactions, such as increased 
cell proliferation and cell survival. Although nAChRs are the 
primary receptors, binding of nicotine to β-ARs and EGFRs may 
also be important. Nicotine induces EMT, which is involved in the 
acquisition of malignant phenotype. Moreover, nicotine induces 
changes that mimic the effects of angiogenic growth factors.
At present, it is not possible to draw a conclusion whether 
nicotine itself may act as a complete carcinogen. In mice stud-
ies with NNK as an initiator, nicotine acts as a promoter after 
injection or dermal absorption, but not after oral administration. 
In drinking water experiments, there is considerable first-pass 
metabolism of nicotine before nicotine enters the systemic cir-
culation. As a result, serum concentration is much lower after 
ingestion than after i.p. administration. Nicotine enhanced tumor 
growth and progression after injection of malignant cells in mice. 
Enhancements were found both after exposure of nicotine by i.p. 
injection, oral, and skin administration. Moreover, cotinine did 
also enhance tumor growth.
Nicotine may inhibit antitumor immune response. It has 
also been reported that exposure to nicotine adversely affects 
dendritic cells, a cell type that has an important role in anticancer 
immunosurveillance. Moreover, in studies on xenograft in mice, 
nicotine has been found to reduce the effect of RT and CRT.
Reduced overall survival and specific disease survival after 
cancer diagnoses have been found among current smokers com-
pared with never smokers, as well as in users of smokeless tobacco, 
such as snus, even for cancers thought to be unrelated to tobacco. 
Although more studies on health effects of nicotine in humans are 
required, based on in vitro and in vivo effects of nicotine, patients 
should be advised not to use nicotine products during cancer 
treatment unless it is temporarily needed to stop tobacco smoking.
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